Introduction For those living with Vascular Ehlers-Danlos Syndrome (VEDS) or supporting loved ones with this condition, staying updated on research developments can provide valuable information. New studies continue to emerge that help us better understand how medications might reduce the risk of serious complications in VEDS. Here, we share summaries of two recent research articles that provide important insights…
As we continue to advance our understanding of Vascular Ehlers-Danlos syndrome (VEDS) and seek effective treatments, it’s crucial to stay updated on the progress of ongoing human trials. Here are the latest developments in two key trials that hold promise for our community: Celiprolol Trial Update: In a significant industry development, Acer Therapeutics was acquired by Florida-based Zevra Therapeutics,…
Statement from The Marfan Foundation with respect to FDA rejection of celiprolol for exclusive use in treatment of individuals with Vascular Ehlers-Danlos syndrome to prevent or control aneurysm, dissection, and rupture of major arteries On June 25, 2019, the FDA announced that it has rejected Acer Therapeutics’ application for exclusive use of the third generation beta blocker celiprolol in…
